San Diego, November 4, 2025 — Kura Oncology, Inc. (Nasdaq: KURA) reported third-quarter 2025 financial results and provided a corporate update. The company’s New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025.
KOMET 017 Phase 3 trials evaluating ziftomenib with chemotherapy in frontline AML are accelerating, investigating settings representing over 50% of AML patients. Oral presentations at the 2025 ASH Annual Meeting will cover ziftomenib with venetoclax/azacitidine chemotherapy in frontline and R/R NPM1-m AML.
Clinical data at ESMO 2025 Congress highlighted the promise of Kura’s second strategic program. FTIs darlifarnib and tipifarnib show promising safety and clinical activity with targeted therapies in solid tumors. With $609.7 million in pro forma cash and anticipated collaboration payments, Kura expects to support the ziftomenib AML program through topline results in KOMET-017.
Kura Oncology’s management is hosting a live webcast and conference call today at 8:00 a.m. ET to discuss the financial results for the third quarter of 2025 and to provide a corporate update.
Investor and Media Contact: Greg Mann, 858-987-4046, gmann@kuraoncology.com
Source: Kura Oncology
